JAK抑制剂在皮肤病学中的应用:一类新药的希望
本文综述JAK-STAT信号通路在多种炎症性皮肤病中的作用,并总结JAK抑制剂在特应性皮炎、斑秃、银屑病和白癜风中的疗效证据。JAK抑制剂可口服或外用,代表一类有前景的新药。
要点
- JAK-STAT是多种促炎信号通路汇聚的细胞内通路。
- JAK抑制剂在特应性皮炎、斑秃、银屑病和白癜风中显示有效。
- JAK抑制剂可口服或外用,早期报告提示对其他皮肤病也可能有效。
核心结论
- JAK抑制剂可能对依赖JAK-STAT信号通路的炎症性皮肤病是有用的治疗策略。
- JAK抑制剂代表一类有前景的新药,可口服或外用。
研究设计与样本
- 本文为综述,回顾JAK抑制剂在皮肤病学中的应用。
主要发现
- 不断增加的证据提示JAK抑制剂在特应性皮炎、斑秃、银屑病和白癜风中有效。
- 早期报告提示JAK抑制可能广泛用于皮肤病学中的其他情况。
临床怎么用
- JAK抑制剂可口服或外用用于皮肤病治疗。
- JAK抑制剂可能用于特应性皮炎、斑秃、银屑病和白癜风。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
New molecularly targeted therapeutics are changing dermatologic therapy. Janus kinase-signal transducer and activator of transcription (JAK-STAT) is an intracellular signaling pathway upon which many different proinflammatory signaling pathways converge. Numerous inflammatory dermatoses are driven by soluble inflammatory mediators, which rely on JAK-STAT signaling, and inhibition of this pathway using JAK inhibitors might be a useful therapeutic strategy for these diseases. Growing evidence suggests that JAK inhibitors are efficacious in atopic dermatitis, alopecia areata, psoriasis, and vitiligo. Additional evidence suggests that JAK inhibition might be broadly useful in dermatology, with early reports of efficacy in several other conditions. JAK inhibitors can be administered orally or used topically and represent a promising new class of medications. The use of JAK inhibitors in dermatology is reviewed here.
引用
- Damsky W, King BA. JAK inhibitors in dermatology: The promise of a new drug class. J Am Acad Dermatol. 2017. PMID: 28139263. doi:10.1016/j.jaad.2016.12.005
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。